GlassScriptPhysician profile
Cody J Harrison
NPI 1528556677
$761.28
in general payments reported to CMS, 2019-2025
14 companies · $16.84 in 2025
The $16.84 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $62.26 · 2021: $71.67 · 2022: $92.52 · 2023: $177 · 2024: $55.75 · 2025: $16.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $249.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $138.59 | 2019-2022 | |
| Abbvie INC. | $90.07 | 2022-2023 | |
| Johnson & Johnson Vision Care, INC. | $70.37 | 2019-2020 | |
| Oyster Point Pharma, INC. | $62.44 | 2022-2023 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $62.32 | 2019 | |
| Alcon Vision LLC | $56.12 | 2019-2023 | Eysuvis |
| Visioneering Technologies, INC. | $49.48 | 2019 | |
| Sun Pharmaceutical Industries INC. | $45.30 | 2020-2024 | |
| Johnson & Johnson Surgical Vision, INC. | $39.02 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $37.94 | 2023 | Vyzulta, Prolensa, Lotemax Sm |
| Shire North American Group INC | $33.24 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $32.75 | 2024 | Xdemvy |
| Coopervision INC. | $32.55 | 2023-2025 | Clariti Contact Lens, Biofinity Contact Lens |
| Tearlab Corp | $11.09 | 2023 | Tearlab Osmolarity System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.